Exacerbation frequency and course of COPD

International Journal of COPD

Volumn 7, Issue , 2012, Pages 653-661

  Halpin, David M G ^a   Decramer, Marc ^b   Celli, Bartolome ^c   Kesten, Steven ^d   Liu, Dacheng ^d   Tashkin, Donald P ^e  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Exacerbations; Forced expiratory volume in one second; Health status; Tiotropium

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH STATUS; HOSPITALIZATION; HUMAN; INHALER; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SPIROMETRY; ST GEORGE RESPIRATORY QUESTIONNAIRE; DRUG EFFECT; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; CHOLINERGIC ANTAGONISTS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; LUNG; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCOPOLAMINE DERIVATIVES; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84872237352     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S34186     Document Type: Article

References (30)

1. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-1422.
2. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58(7):589-593.
3. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis. 2009;4:245-251.
4. Bates DV. The fate of the chronic bronchitic: a report of the ten-year follow-up in the Canadian Department of Veteran's Affairs coordinated study of chronic bronchitis. The J Burns Amberson Lecture of the American Thoracic Society: Am Rev Respir Dis. 1973;108(5): 1043-1065.
5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
6. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164(3):358-364.
7. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003;163(10):1180-1186.
8. Price LC, Lowe D, Hosker HS, Anstey K, Pearson MG, Roberts CM. UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax. 2006;61(10):837-842.
9. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-224.
10. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124(5):1743-1748.
11. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168-1178.
12. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832-840.
13. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15): 1543-1554.
14. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design consider-ations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004;1(2):303-312.
15. [No authors listed]. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(3): 1107-1136.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-com-plete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6):1321-1327.
17. Fletcher C, Peto R, Tinker C, Speizer F. The Natural History of Chronic Bronchitis and Emphysema. An 8 Year Study of Working Men. Oxford, UK: Oxford University Press; 1976.
18. Kosmas EN, Zorpidou D, Vassilareas V, Roussou T, Michaelides S. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest. 1997;112(2):341-347.
19. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflamma-tion in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J. 2000;15(2):274-280.
20. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17(6):1112-1119.
21. Viglio S, Iadarola P, Lupi A, et al. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J. 2000;15(6):1039-1045.
22. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest. 2000;118(6):1557-1565.
23. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51(3):267-271.
24. Llor C, Molina J, Naberan K, Cots JM, Ros F, Miravitlles M. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract. 2008;62(4): 585-592.
25. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387-395.
26. Miravitlles M, Calle M, Alvarez-Gutierrez F, Gobartt E, Lopez F, Martin A. Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease. Qual Life Res. 2006;15(3):471-480.
27. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23(5):698-702.
28. Halpin D. Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. COPD. 2008;5(3):187-200.
29. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931.
30. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12): 1128-1138.